SAFETY, TOLERABILITY AND EFFICACY OF SUBCUTANEOUS ADMINISTRATION OF DARATUMUMAB IN PATIENTS WITH MULTIPLE MYELOMA: EXPERIENCE IN A TERTIARY CENTER

被引：0
|
作者：
Gutierrez, Lopez de Ocariz X. [1 ]
Cuellar, Perez-Avila C. [1 ]
De Nicolas, Sol R. [1 ]
Buendia, Urena B. [1 ]
Vera, Guerrero E. [1 ]
Hidalgo, Soto M. [1 ]
Lopez, Munoz N. [1 ]
Zamanillo, Herreros, I [1 ]
Iniguez, Garcia R. [1 ]
Poza, Santaella M. [1 ]
Sanchez, Pina J. M. [1 ]
Alonso, Fernandez R. [1 ]
Lahuerta, Palacios J. J. [1 ]
Martinez, Lopez J. [1 ]
机构：
[1] Hosp Univ 12 Octubre, Madrid, Spain
来源：
HAEMATOLOGICA | 2020年 / 105卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
PO-017
引用
收藏
页码：144 / 145
页数：2
相关论文
共 50 条
  • [1] SAFETY AND TOLERABILITY OF RAPID INTRAVENOUS INFUSION OF DARATUMUMAB IN PATIENTS WITH MULTIPLE MYELOMA: EXPERIENCE IN A TERTIARY CENTER
    Gutierrez, Lopez de Ocariz X.
    Cuellar, Perez-Avila C.
    Vera, Guerrero E.
    De Nicolas, Sol R.
    Buendia, Urena B.
    Lopez, Munoz N.
    Hidalgo, Soto M.
    Zamanillo, Herreros, I
    Poza, Santaella M.
    Iniguez, Garcia R.
    Sanchez, Pina J. M.
    Alonso, Fernandez R.
    Lahuerta, Palacios J. J.
    Martinez, Lopez J.
    [J]. HAEMATOLOGICA, 2020, 105 : 146 - 146
  • [2] Safety of Subcutaneous Daratumumab/ Hyaluronidase after Intravenous Daratumumab for Patients with Multiple Myeloma
    Copley, Melissa
    Metheny, Leland
    Klisovic, Rebecca B.
    Malek, Ehsan
    [J]. BLOOD, 2022, 140 : 13202 - 13203
  • [3] Multiple Myeloma: Extension of Approval for subcutaneous Administration of Daratumumab
    不详
    [J]. ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (7-8) : 397 - 397
  • [4] Safety and blood levels of daratumumab after switching from intravenous to subcutaneous administration in patients with multiple myeloma
    Yamaoka, Kenta
    Irie, Kei
    Hiramoto, Nobuhiro
    Hirabatake, Masaki
    Ikesue, Hiroaki
    Hashida, Tohru
    Shimizu, Tadashi
    Ishikawa, Takayuki
    Muroi, Nobuyuki
    [J]. INVESTIGATIONAL NEW DRUGS, 2023, 41 (05) : 761 - 767
  • [5] Safety and blood levels of daratumumab after switching from intravenous to subcutaneous administration in patients with multiple myeloma
    Kenta Yamaoka
    Kei Irie
    Nobuhiro Hiramoto
    Masaki Hirabatake
    Hiroaki Ikesue
    Tohru Hashida
    Tadashi Shimizu
    Takayuki Ishikawa
    Nobuyuki Muroi
    [J]. Investigational New Drugs, 2023, 41 : 761 - 767
  • [6] Efficacy and Safety of Durvalumab Combined with Daratumumab in Daratumumab-Refractory Multiple Myeloma Patients
    Frerichs, Kristine A.
    Verkleij, Christie P. M.
    Dimopoulos, Meletios A.
    Marin Soto, Jhon A.
    Zweegman, Sonja
    Young, Mary H.
    Newhall, Kathryn J.
    Mutis, Tuna
    van de Donk, Niels W. C. J.
    [J]. CANCERS, 2021, 13 (10)
  • [7] Clinical Administration Characteristics of Subcutaneous and Intravenous Administration of Daratumumab in Multiple Myeloma Patients at Mayo Clinic
    Soefje, Scott
    Carpenter, Corinne
    Carlson, Katherine
    Awasthi, Samir
    Lin, Thomas S.
    Kaila, Shuchita
    Tarjan, Daniel
    Kayal, Nikhil
    Kirkup, Christian
    Wagner, Tyler
    Gray, Kathleen
    Kumar, Shaji
    [J]. BLOOD, 2021, 138
  • [8] Safety and efficacy of daratumumab in patients with multiple myeloma and severe renal failure
    Kuzume, Ayumi
    Tabata, Rikako
    Terao, Toshiki
    Tsushima, Takafumi
    Miura, Daisuke
    Narita, Kentaro
    Takeuchi, Masami
    Matsue, Kosei
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2021, 193 (04) : E33 - E36
  • [9] The efficacy and safety of daratumumab in relapsed and refractory multiple myeloma
    贾亚静
    [J]. China Medical Abstracts (Internal Medicine), 2020, 37 (03) : 189 - 189
  • [10] PATIENTS WITH MULTIPLE MYELOMA TREATED WITH DARATUMUMAB IN COMBINATION. EXPERIENCE IN SINGLE CENTER
    Robredo Rodriguez, B.
    Villanueva Jimenez, P.
    Quesada Sanz, M.
    Sanchez Garcia, M., I
    Delgado Mateos, F.
    Avila Alvarez, J. R.
    Casaus Garcia, A.
    [J]. HAEMATOLOGICA, 2019, 104 : 397 - 397
12345